General Information
Drug ID
DR00716
Drug Name
Vecuronium
Synonyms
(2A,3A,5A,16A,17A)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; (2beta,3alpha,5alpha,16beta,17beta)-3,17-diacetoxy-16-(1-methylpiperidinium-1-yl)-2-(piperidin-1-yl)androstane; Norcuron (TN); [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-acetyloxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate
Drug Type
Small molecular drug
Indication Pain [ICD11: MG30-MG7Z] Approved [1]
Spasms [ICD11: MB47.3] Approved [1]
Therapeutic Class
Analgesics
Structure
3D MOL 2D MOL
Formula
C34H57N2O4+
Canonical SMILES
CC(=O)OC1CC2CCC3C(C2(CC1N4CCCCC4)C)CCC5(C3CC(C5OC(=O)C)[N+]6(CCCCC6)C)C
InChI
InChI=1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
InChIKey
BGSZAXLLHYERSY-XQIGCQGXSA-N
CAS Number
CAS 50700-72-6
Pharmaceutical Properties Molecular Weight 557.8 Topological Polar Surface Area 55.8
Heavy Atom Count 40 Rotatable Bond Count 6
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 5
XLogP
6.5
PubChem CID
39765
PubChem SID
104332628 , 117550021 , 123097011 , 135065904 , 135962408 , 137241739 , 139157515 , 14837446 , 160964634 , 164153588 , 165698506 , 175266821 , 175442172 , 176484500 , 178100828 , 179150509 , 184664916 , 238570034 , 252811085 , 34705625 , 46507656 , 50112721 , 50621251 , 8176218 , 87246434 , 92309078 , 9756
ChEBI ID
CHEBI:9939
TTD Drug ID
D0Z8HG
DT(s) Transporting This Drug P-GP Transporter Info P-glycoprotein 1 Substrate [2]
References
1 Vecuronium was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.